Levodopa-Carbidopa Enteral Suspension (e.g., Duopa) for the Treatment of Parkinson Disease
RX504.015
Levodopa‑carbidopa enteral suspension (e.g., Duopa) and the associated enteral pump DME for treatment of advanced, levodopa‑responsive Parkinson disease with motor fluctuations. Coverage is limited to idiopathic PD patients with bradykinesia plus another cardinal sign, clearly defined "On" periods and ≥3 hours/day disabling "Off" despite optimized therapy (dopamine agonist, oral levodopa/carbidopa and a COMT or MAO‑B inhibitor); patients must be candidates for PEG‑J placement and use must align with FDA labeling or authoritative references, with exclusions for atypical/secondary parkinsonism, concurrent nonselective MAO inhibitor use, and other indications not supported by peer‑reviewed literature or the member’s benefit plan.
"Levodopa-carbidopa enteral suspension (e."
Sign up to see full coverage criteria, indications, and limitations.